

Gibson Dunn Represented Cogent Biosciences in Concurrent Public Offerings of Common Stock and Convertible Notes with Aggregate Gross Proceeds of \$575 Million

Firm News | November 17, 2025

Gibson Dunn represented Cogent Biosciences, Inc., a clinical-stage biotechnology company, in concurrent public offerings of common stock and convertible notes expected to result in aggregate gross proceeds of \$575 million to Cogent.

J.P. Morgan Securities, Jefferies, Leerink Securities, and Guggenheim Securities acted as joint book-running managers for the equity offering, with LifeSci Capital acting as lead manager and Raymond James Acting as co-manager. Jefferies and J.P. Morgan Securities acted as joint book-running managers for the notes offering.

Our team included partners Ryan Murr, Branden Berns, and Stewart McDowell and associates Nick Linke, Candice Johnson, and Jasmine Vitug.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Stewart McDowell](#)

[Nicholas G. Linke](#)

[Candice D. Johnson](#)

[Jasmine L. Vitug](#)

Related Capabilities

[Life Sciences](#)